Global Lung Cancer Vaccine Market & Pipeline Outlook 2022

Description:
“Global Lung Cancer Vaccine Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are 9 lung cancer vaccines in advance Phase-II clinical trials followed by 8 vaccines Phase-I/II trials.

Lung cancer is emerging as one of the most lethal malignancy having high morbidity and mortality rates across the world. High mortality rates, high unmet medical necessities and modest efficacy of presently available lung cancer therapeutics have encouraged the demand for better and efficient lung cancer vaccines. More funds are being diverted into research and development segment to come up with lung cancer vaccine having high safety and efficacy profiles. Pharmaceutical companies have recognized the marketing potential of these vaccines in generating significant revenues and providing efficient medical care to patients across the world. Lung cancer vaccine market is largely untapped and offers significant opportunities to pharmaceutical companies to occupy large market shares across the globe.

At present majority of the lung cancer vaccines are in experimental stage and are still stuck in clinical trials due to which large unmet medical demands are still to be fulfilled. Boehringer Ingelheim and CureVac are developing lung cancer vaccine called CV9202 for the treatment of lung cancer which is at higher phase of clinical trials. GlaxoSmithKline is developing MAGE-A3 lung cancer vaccine which is also under investigation for other malignancies. Cell Genesys pharmaceutical company is developing GVAX for lung cancer and many clinical end points have been achieved during investigation.

Early market introduction of these drugs will be the major factor responsible for the increased marketing potential. Over time, they are expected to generate significant revenues owing to their safety and efficacy levels but till then this gap will be filled by other therapeutics. Further, those lung cancer vaccines which will make late entry have to face competition with previously marketed lung cancer vaccines giving them severe competition. This shows that pharmaceutical companies have to introduce their products in market as soon as possible to occupy major market shares across the globe. Thus, impact of early entrant will be more in global market and help them to generate significant revenues for some time before entry of worthy competitors.

Many pharmaceutical companies have already introduces cancer vaccines in global market and lung cancer segment is expected to get its first contender in coming years. Addition of lung cancer vaccines in this segment will further increase the size of global cancer vaccine market. Several other products belonging to different cancer indication will be entering in the global market leading to further increase in the market size. Advent of lung cancer vaccines is expected to improve this situation by increasing present survival rates and improve quality of life. Introduction of lung cancer vaccines are expected to gain major market shares among other cancer vaccines due to large patient population as compared to other disease indication.

Contents:
1. What are Cancer Vaccines?
2. Mechanism of Cancer Vaccines
   2.1 Idiotype Cancer Vaccine Mechanism
   2.2 Cellular Cancer Vaccines Mechanism
   2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
   2.4 Peptide Cancer Vaccine Mechanism
   2.5 Tumor Host Interaction Cancer Vaccine Mechanism
3. Overview of Lung Cancer Proliferation
   3.1 Lung Cancer Invasion
      3.1.1 Transformation of Normal Cell into Cancerous Cell
      3.1.2 Tumor Heterogeneity & Cancer Stem Cells
      3.1.3 Dissemination of Tumor Cell & Cell Motility
3.2 Lung Cancer Metastasis
3.2.1 Angiogenesis & Lymphangiogenesis
3.2.2 Intravasation, Circulation & Extravasation

4. Lung Cancer Vaccine Mechanism
4.1 Mechanism of Lung Cancer Vaccination
4.2 Rationale for Using Lung Cancer Vaccines
4.2.1 Regulatory T- Lymphocytes (Tregs)
4.2.2 Macrophages

5. Clinical Trials of Lung Cancer Vaccines

6. Global Lung Cancer Incidence Rate
6.1 U.S
6.2 Europe
6.3 Asia
6.4 Rest of the World

7. Global Lung Cancer Vaccine Market Overview
7.1 Current Market Scenario
7.2 Global Lung Cancer Vaccine Pipeline Overview
7.3 Global Lung Cancer Vaccine Market Future Prospects

8. Need for Personalized Breast Cancer Vaccines

9. Lung Cancer Vaccine Clinical Pipeline by Company & Phase
9.1 Preclinical
9.2 Phase-I
9.3 Phase-II

10. Non Small Cell Lung Cancer Vaccine Clinical Pipeline by Company & Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-II/III
10.7 Phase-III

11. Small cell Lung Cancer Vaccine Clinical Pipeline by Company & Phase
11.1 Phase-II

12. Marketed Lung Cancer Vaccine Clinical & Patent Insight
12.1 Epidermal Growth Factor Cancer Vaccine
12.2 Mycidac-C™
12.3 Racotumomab (Vaxira)

13. No Development Reported & Discontinued Lung Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

14. Competitive Landscape
14.1 Argos Therapeutics
14.2 Boehringer Ingelheim
14.3 Cadila Pharmaceuticals
14.4 CureVac
14.5 Eli Lily
14.6 Galaxo
14.7 ImClone Systems
14.8 Inovio Pharmaceuticals
14.9 Merck
List of Figures:
- Figure 1-1: Categorization & Function of Cancer Vaccines
- Figure 2-1: Classification of Different Types of Cancer vaccines
- Figure 3-1: Major Steps Involved in Cancer Invasiveness
- Figure 4-1: Mechanism of Lung Cancer Vaccination
- Figure 6-1: US - Lung Cancer New Incidence & Deaths, 2016
- Figure 6-2: US - Lung Cancer New Incidence by Gender, 2016
- Figure 6-3: US - Lung Cancer Deaths by Gender, 2016
- Figure 6-4: Japan - Lung Cancer New Incidence & Deaths, 2016
- Figure 6-5: Japan - Lung Cancer New Incidence by Gender, 2016
- Figure 6-6: Japan - Lung Cancer Deaths by Gender, 2016
- Figure 6-7: China - Lung Cancer Patients, 2016 & 2022
- Figure 6-8: India - Lung Cancer New Incidence, 2016 & 2022
- Figure 6-9: Canada - Lung Cancer Deaths by Gender, 2016
- Figure 7-1: Global Lung Cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
- Figure 7-2: Global Lung Cancer Vaccine Clinical Pipeline by Phase (Numbers), 2016 till 2022
- Figure 7-3: Global Non-small cell lung cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
- Figure 7-4: Global Non-small cell lung cancer Vaccine Clinical Pipeline by Phase (Number), 2016 till 2022
- Figure 7-5: Global Lung Cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
- Figure 7-6: Global Lung Cancer Vaccine Clinical Pipeline by Phase (Numbers), 2016 till 2022
- Figure 8-1: Overview of Personalized Cancer Vaccines Development
- Figure 8-2: Methodology for the Development of Personalized Cancer Vaccine
- Figure 8-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
- Figure 14-1: Inovio Pharmaceuticals Clinical Pipeline
- Figure 14-2: NewLink Genetics Corporation Clinical Pipeline
- Figure 14-3: Northwest Biotherapeutics Clinical Pipeline

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/4013368/](http://www.researchandmarkets.com/reports/4013368/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Global Lung Cancer Vaccine Market & Pipeline Outlook 2022
- **Web Address:** [http://www.researchandmarkets.com/reports/4013368/](http://www.researchandmarkets.com/reports/4013368/)
- **Office Code:** SC2GBN6F

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 2000</td>
<td></td>
</tr>
<tr>
<td>Single User</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD-ROM</td>
<td>USD 2400 + USD 56 Shipping/Handling</td>
<td></td>
</tr>
<tr>
<td>Hard Copy</td>
<td>USD 3000 + USD 56 Shipping/Handling</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 3600</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:** Mr [ ]  Mrs [ ]  Dr [ ]  Miss [ ]  Ms [ ]  Prof [ ]
- **First Name:**
- **Last Name:**
- **Email Address:** *
- **Job Title:**
- **Organisation:**
- **Address:**
- **City:**
- **Postal / Zip Code:**
- **Country:**
- **Phone Number:**
- **Fax Number:**

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
</tbody>
</table>
| Bank Address      | Ulster Bank,
                   | 27-35 Main Street,
                   | Blackrock,
                   | Co. Dublin,
                   | Ireland. |

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World